SYK and melanoma: Our results show that a Syk inhibitor can partially block platelet aggregation and pulmonary metastasis in vitro and in vivo, which demonstrates that the syk-dependent signalling pathway in the podoplanin-CLEC-2 interaction plays a role in platelet aggregation and melanoma pulmonary metastasis.